Erythema Annulare Centrifugum
- Author: Marisel Peralta-Abejo, MD, DPDS; Chief Editor: William D James, MD more...
Erythema annulare centrifugum (EAC) is classified as one of the figurate or gyrate erythemas. First described by Darier in 1916, it is characterized by a scaling or nonscaling, nonpruritic, annular or arcuate, erythematous eruption. It tends to spread peripherally while clearing centrally. Histologically, an intense lymphohistiocytic cuffing occurs about the superficial and deep dermal vessels without epidermal involvement. The etiology is uncertain, but it may be due to a hypersensitivity to malignancy, infection, drugs, or chemicals, or it may be idiopathic.
Controversy exists in the classification of the gyrate erythemas, and the literature is wrought with ambiguity and contradictions. Since its initial description in 1916, the term erythema annulare centrifugum has grown to include several histologic and clinical variants. Ackerman, and later Bressler and Jones, suggested a classification in which only 2 types of gyrate erythema are considered: superficial (pruritic, scaling) and deep (nonpruritic, nonscaling). The original description of EAC was of the latter type. However, the superficial type is more commonly seen with its characteristic trailing scale behind an advancing, erythematous border.
In this article, EAC is considered to include all the gyrate erythemas, except for erythema marginatum rheumaticum, erythema chronicum migrans, and erythema gyratum repens. When taken in this broad sense, EAC can be scaly or nonscaly, pruritic or nonpruritic, and rarely vesicular.
Other Medscape erythema articles include the following:
The pathogenesis of erythema annulare centrifugum (EAC) is unknown, but it is probably due to a hypersensitivity reaction to a variety of agents, including drugs, arthropod bites, infections (bacterial, mycobacterial, viral, fungal, filarial), ingestion (blue cheese Penicillium), and malignancy. Injections of Trichophyton, Candida, tuberculin, and tumor extracts have been reported to induce EAC, supporting a type IV hypersensitivity reaction as at least one mechanism for its development. Another purported mechanism in the pathogenesis of EAC is that of a Th1-mediated reaction with elevated levels of tumor necrosis factor-alpha and associated proinflammatory cytokines. Minni and Sarro reported response to (and relapse following cessation of) etanercept in a 57-year-old white man as evidence supporting this theory.
Other cases of EAC have been found in association with an underlying systemic or infectious disease (eg, liver disease, Sjögren syndrome, systemic lupus erythematosus, Graves disease, hypereosinophilic syndrome, appendicitis ), herpes zoster, chronic lymphocytic leukemia, and HIV disease. Drugs reported to cause EAC include finasteride, piroxicam, hydroxychloroquine, amitriptyline, and spironolactone. Still other cases have been attributable to a familial form. However, in most cases, no underlying cause can be found. One study of 24 cases of EAC with special reference to its association with an underlying disease found no increased incidence of systemic disease, malignancy, or infection. In another study of 113 cases of gyrate erythemas, 7 cases (none of which was erythema gyratum repens) were associated with internal malignancy compared with 6 cases in the control group.
Hypotheses about the mechanism of annularity focus on the interaction between mediators of inflammation and ground substance as foreign antigens diffuse through the skin.
Defining the incidence and the prevalence of erythema annulare centrifugum (EAC) is difficult because the literature mostly consists of case reports and brief reviews. In a review of 24 cases in England, the incidence was reported to be approximately 1 case per 100,000 population per year in a catchment area of 500,000 people.
Whether any racial predilection exists for erythema annulare centrifugum (EAC) is not known.
No bias for either sex is apparent for erythema annulare centrifugum (EAC).
Erythema annulare centrifugum (EAC) has been reported in patients from infancy to the ninth decade of life.
The prognosis for erythema annulare centrifugum (EAC) is excellent, except when associated with an underlying malignancy and other systemic disease. The mean duration of erythema annulare centrifugum (EAC) is 11 months. However, the course has ranged from 4-6 weeks to 34 years (recurrent attacks). Most cases require no treatment and resolve spontaneously. Others have been reported in association with malignancy, with the eruptions responding to treatment of the underlying neoplasm. In those cases, the prognosis is affected by the underlying malignancy. Annually recurring erythema annulare centrifugum (AR EAC) was reported in 2015. Treatment of the underlying disorder is effective. If associated with pregnancy, it resolves after delivery.
Bressler GS, Jones RE Jr. Erythema annulare centrifugum. J Am Acad Dermatol. 1981 May. 4(5):597-602. [Medline].
Minni J, Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol. 2006 Mar. 54(3 Suppl 2):S134-5. [Medline].
Tsuji T, Kadoya A. Erythema annulare centrifugum associated with liver disease. Arch Dermatol. 1986 Nov. 122(11):1239-40. [Medline].
Braunstein BL. Erythema annulare centrifugum and Graves' disease. Arch Dermatol. 1982 Sep. 118(9):623. [Medline].
Shelley WB, Shelley ED. Erythema annulare centrifugum as the presenting sign of the hypereosinophilic syndrome: observations on therapy. Cutis. 1985 Jan. 35(1):53-5. [Medline].
Sack DM, Carle G, Shama SK. Recurrent acute appendicitis with erythema annulare centrifugum. Arch Intern Med. 1984 Oct. 144(10):2090-2. [Medline].
Ohmori S, Sugita K, Ikenouci-Sugita A, Nakamura M. Erythema annulare centrifugum associated with herpes zoster. J UOEH. 2012 Sep 1. 34(3):225-9. [Medline].
Mahood JM. Erythema annulare centrifugum: a review of 24 cases with special reference to its association with underlying disease. Clin Exp Dermatol. 1983 Jul. 8(4):383-7. [Medline].
Mandel VD, Ferrari B, Manfredini M, Giusti F, Pellacani G. Annually recurring erythema annulare centrifugum: a case report. J Med Case Rep. 2015 Oct 22. 9:236. [Medline].
Carlesimo M, Fidanza L, Mari E, et al. Erythema annulare centrifugum associated with mantle b-cell non-Hodgkin's lymphoma. Acta Derm Venereol. 2009. 89(3):319-20. [Medline].
Halevy S, Cohen AD, Lunenfeld E, Grossman N. Autoimmune progesterone dermatitis manifested as erythema annulare centrifugum: Confirmation of progesterone sensitivity by in vitro interferon-gamma release. J Am Acad Dermatol. 2002 Aug. 47(2):311-3. [Medline].
Rosina P, D'Onghia FS, Barba A. Erythema annulare centrifugum and pregnancy. Int J Dermatol. 2002 Aug. 41(8):516-7. [Medline].
Burkhart CG. Erythema annulare centrifugum. A case due to tuberculosis. Int J Dermatol. 1982 Nov. 21(9):538-9. [Medline].
White JW Jr. Gyrate erythema. Dermatol Clin. 1985 Jan. 3(1):129-39. [Medline].
Borbujo J, de Miguel C, Lopez A, de Lucas R, Casado M. Erythema annulare centrifugum and Escherichia coli urinary infection. Lancet. 1996 Mar 30. 347(9005):897-8. [Medline].
Hendricks AA, Lu C, Elfenbein GJ, Hussain R. Erythema annulare centrifugum associated with ascariasis. Arch Dermatol. 1981 Sep. 117(9):582-5. [Medline].
Bessis D, Chraibi H, Guillot B, Guilhou JJ. Erythema annulare centrifugum induced by generalized Phthirus pubis infestation. Br J Dermatol. 2003 Dec. 149(6):1291. [Medline].
Hammar H. Erythema annulare centrifugum coincident with Epstein-Barr virus infection in an infant. Acta Paediatr Scand. 1974 Sep. 63(5):788-92. [Medline].
Lee HW, Lee DK, Rhee DY, Chang SE, Choi JH, Moon KC, et al. Erythema annulare centrifugum following herpes zoster infection: Wolf's isotopic response?. Br J Dermatol. 2005 Dec. 153(6):1241-3. [Medline].
González-Vela MC, González-López MA, Val-Bernal JF, Echevarría S, Arce FP, Fernández-Llaca H. Erythema annulare centrifugum in a HIV-positive patient. Int J Dermatol. 2006 Dec. 45(12):1423-5. [Medline].
García-Doval I, Peteiro C, Toribio J. Amitriptyline-induced erythema annulare centrifugum. Cutis. 1999 Jan. 63(1):35-6. [Medline].
Turan Erkek E, Kalayoğlu Beşışık S. An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum. Turk J Haematol. 2016 Mar 5. 33 (1):81-82. [Medline].
Kuroda K, Yabunami H, Hisanaga Y. Etizolam-induced superficial erythema annulare centrifugum. Clin Exp Dermatol. 2002 Jan. 27(1):34-6. [Medline].
Hudson LD. Erythema annulare centrifugum: an unusual case due to hydroxychloroquine sulfate. Cutis. 1985 Aug. 36(2):129-30. [Medline].
Gönül M, Külcü Çakmak S, Ozcan N, Deniz Oguz I, Ozhamam E. Erythema annulare centrifugum due to pegylated interferon-a-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. J Cutan Med Surg. 2014 Jan-Feb. 18(1):65-8. [Medline].
Mendes-Bastos P, Coelho-Macias V, Moraes-Fontes MF, Milheiro A, Rodrigues AM, Cardoso J. Erythema annulare centrifugum during rituximab treatment for autoimmune haemolytic anaemia. J Eur Acad Dermatol Venereol. 2014 Aug. 28(8):1125-7. [Medline].
Chou WT, Tsai TF. Recurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient. Acta Derm Venereol. 2013 Mar 27. 93(2):208-9. [Medline].
Everall JD, Dowd PM, Ardalan B. Unusual cutaneous associations of a malignant carcinoid tumour of the bronchus--erythema annulare centrifugum and white banding of the toe nails. Br J Dermatol. 1975 Sep. 93(3):341-5. [Medline].
Leimert JT, Corder MP, Skibba CA, Gingrich RD. Erythema annulare centrifugum and Hodgkin's disease: association with disease activity. Arch Intern Med. 1979 Apr. 139(4):486-7. [Medline].
Yaniv R, Shpielberg O, Shpiro D, Feinstein A, Ben-Bassat I. Erythema annulare centrifugum as the presenting sign of Hodgkin's disease. Int J Dermatol. 1993 Jan. 32(1):59-61. [Medline].
Panasiti V, Devirgiliis V, Curzio M, Rossi M, Roberti V, Bottoni U, et al. Erythema annulare centrifugum as the presenting sign of breast carcinoma. J Eur Acad Dermatol Venereol. 2009 Mar. 23(3):318-20. [Medline].
Ioannidou D, Krasagakis K, Stefanidou M, Tosca A. Erythema annulare centrifugum and osteoarthritis treated with hyaluronic acid. Clin Exp Dermatol. 2002 Nov. 27(8):720-2. [Medline].
Ibrahim SF, Pryor J, Tausk FA. Stress-induced erythema annulare centrifugum. Dermatol Online J. 2009 Apr 15. 15(4):15. [Medline].
Dogan G. Pregnancy as a possible etiologic factor in erythema annulare centrifugum. Am J Clin Dermatol. 2009. 10(1):33-5. [Medline].
Cotterman C, Eckert L, Ackerman L. Syphilis mimicking tinea imbricata and erythema annulare centrifugum in an immunocompromised patient. J Am Acad Dermatol. 2009 Jul. 61(1):165-7. [Medline].
Chodkiewicz HM, Cohen PR. Paraneoplastic erythema annulare centrifugum eruption: PEACE. Am J Clin Dermatol. 2012 Aug 1. 13(4):239-46. [Medline].
Guillet MH, Dorval JC, Larrégue M, Guillet G. [Darier's erythema annulare centrifugum of neonatal onset with a 15 years' follow-up. Efficacy of interferon and role of cytokines]. Ann Dermatol Venereol. 1995. 122(6-7):422-6. [Medline].
Gniadecki R. Calcipotriol for erythema annulare centrifugum. Br J Dermatol. 2002 Feb. 146(2):317-9. [Medline].
Reuter J, Braun-Falco M, Termeer C, Bruckner-Tuderman L. [Erythema annulare centrifugum Darier. Successful therapy with topical calcitriol and 311 nm-ultraviolet B narrow band phototherapy]. Hautarzt. 2007 Feb. 58(2):146-8. [Medline].
De Aloe G, Rubegni P, Risulo M, Sbano P, Poggiali S, Fimiani M. Erythema annulare centrifugum successfully treated with metronidazole. Clin Exp Dermatol. 2005 Sep. 30(5):583-4. [Medline].
Chuang FC, Lin SH, Wu WM. Erythromycin as a Safe and Effective Treatment Option for Erythema Annulare Centrifugum. Indian J Dermatol. 2015 Sep-Oct. 60 (5):519. [Medline].